Fiera Capital Corp Has $43.25 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Fiera Capital Corp decreased its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 592,415 shares of the biopharmaceutical company’s stock after selling 13,112 shares during the quarter. Fiera Capital Corp’s holdings in Insmed were worth $43,246,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of INSM. Darwin Global Management Ltd. bought a new stake in Insmed during the second quarter worth approximately $237,076,000. Capital International Investors acquired a new position in Insmed in the 1st quarter valued at $43,973,000. Clearbridge Investments LLC bought a new position in Insmed in the 1st quarter worth $25,242,000. Farallon Capital Management LLC acquired a new position in Insmed during the 2nd quarter worth $38,056,000. Finally, Fred Alger Management LLC bought a new stake in Insmed during the second quarter valued at about $33,404,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a research note on Thursday, October 3rd. Truist Financial reiterated a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Morgan Stanley boosted their target price on shares of Insmed from $60.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 12th. StockNews.com cut shares of Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Finally, TD Cowen raised their price target on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $83.07.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares in the company, valued at $7,157,150. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares of the company’s stock, valued at $7,951,559.28. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,882 shares of company stock valued at $5,765,446. Corporate insiders own 4.60% of the company’s stock.

Insmed Price Performance

INSM stock traded up $0.41 during trading on Friday, hitting $72.10. The company had a trading volume of 233,293 shares, compared to its average volume of 2,255,116. The company has a fifty day moving average price of $72.57 and a two-hundred day moving average price of $62.52. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The company has a market cap of $12.90 billion, a P/E ratio of -12.89 and a beta of 1.12. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The business’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.10) EPS. Equities research analysts expect that Insmed Incorporated will post -5.52 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.